Sam Altman-Backed Retro Biosciences Secures $1 Billion to Revolutionize Human Lifespan Extension
OpenAI CEO Sam Altman is making significant investments in the biotech sector, particularly with his commitment to Retro Biosciences. This San Francisco-based startup aims to extend the healthy human lifespan by an impressive 10 years, revolutionizing the field of longevity research.
Sam Altman’s Investment in Retro Biosciences
Previously, Altman funded Retro Biosciences with a substantial $180 million seed round. According to a report by the Financial Times, the startup is now in the process of raising a remarkable $1 billion Series A, with Altman once again stepping in to support its mission.
Innovative Research and Drug Development
Retro Biosciences is at the forefront of biotechnology, focusing on groundbreaking research aimed at treating diseases such as Alzheimer’s. Recently, the startup has collaborated with OpenAI to develop a model that transforms regular cells into stem cells, showcasing its commitment to innovation.
CEO’s Vision for the Future
CEO Joe Betts-LaCroix has expressed a strong desire to expedite the drug discovery and development process. He aims to bring a new drug to market “in the 2020s,” which could potentially change the landscape of longevity and healthcare.
Competing in the Longevity Sector
Retro Biosciences is not alone in its quest for extending life. Other notable billionaire-backed projects in the longevity space include:
- Altos Labs: Launched in 2022 with a whopping $3 billion in funding from Jeff Bezos.
- Unity Biotechnology: Supported by both Jeff Bezos and Peter Thiel, focusing on age-related diseases.
With such robust backing and innovative approaches, Retro Biosciences is poised to make a significant impact in the biotech industry. For more information on the latest advancements in biotech and longevity research, visit Biotech News.